KRAZATI®
(adagrasib)
BRISTOL-MYERS SQUIBB
HK Reg. No. HK-68516 (18 Dec, 2024)
Composition:4
• White to off-white, oval shaped, film-coated tablet, approximately 8 x 16 mm, with a stylized “M” on one side and “200” marked on the other side. Each film-coated tablet contains 200 mg adagrasib
Indication:4
• Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy
References
1. Therapeutic Goods Administration, Australia. Product Information. 18 March 2024. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2022-PI-01599-1&d=20250103172310101. [Accessed 3 January 2025]. 2. European Medicines Agency. Summary of Product Characteristics. Available from: https://ec.europa.eu/health/documents/community-register/2023/20231201161202/anx_161202_en.pdf. [Accessed 3 January 2025]. 3. EMC. Quofenix 300 mg powder for concentrate for solution for infusion SmPC. Available from: https://www.medicines.org.uk/emc/product/11481/smpc#about-medicine. [Accessed 3 January 2025]. 4. European Medicines Agency. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf. [Accessed 3 January 2025].
